Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today ...

Enzyme Replacement Therapy for Pompe Disease Market to Reach $350 Million by 2025, Driven by Expanding Clinical Applications The global enzyme replacement therapy (ERT) targeting Pompe disease market ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Gena Wang of ...

Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One Dr. Vasconcelles to drive ...

News Published: March 2008 Genzyme and Isis strike megadeal George S. Mack Nature Biotechnology 26, 251–252 (2008) Cite this article ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

Genzyme continued to drive growth for Sanofi in the first quarter, helped along by the company’s vaccines unit, but diabetes drugs are still struggling. Net sales were €8,391 million, an ...

Mark Joseph Enyedy currently works at BioMarin Pharmaceutical, Inc., as Independent Director from 2023, Charles River Laboratories International, Inc., as Independent Director from 2025, and ...